Targeting the Proteasome in Cancer Therapy
KeywordsMultiple Myeloma Programme Cell Death Proteasome Inhibitor Mantle Cell Lymphoma Liposomal Doxorubicin
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- Aghajanian C, Dizon D, Yan XJ, et al., (2003). Phase I trial of PS-341 and carboplatin in recurrent ovarian cancer. Proc Amer Soc Clin Oncol, 22:452, Abstract 1815.Google Scholar
- An B, Goldfarb RH, Siman R & Dou QP. (1998). Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ, 5:1062–75.PubMedGoogle Scholar
- Bladé J, Samson D, Reece D, et al., (1998). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the European Group for Blood and Marrow Transplant. Br J Haematol, 102:1115–23.PubMedGoogle Scholar
- Bosland M. (2003). Bombesin stimulates nuclear factor kappa B activation and expression of pro-angiogenic factors in prostate cancer cells. Urol Oncol, 21:415.Google Scholar
- Dees EC, O’Neil B, Humes E, et al., (2003). Phase I trial of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory solid tumors. Proc American Soc Clin Oncol, 22:217, Abstract 868.Google Scholar
- Fredersdorf S, Burns J, Milne AM, et al., (1997). High level expression of p27Kipl and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27Kipl and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA, 94:6380–5.PubMedGoogle Scholar
- Goy A, Hart S, Pro B, et al., (2003). Report of a phase II study of proteasome inhibitor bortezomib (VELCADE®) in patients with relapsed or refractory indolent or aggressive lymphomas. Blood, 102:180a, Abstract 627.Google Scholar
- Jagannath S, Durie BGM, Wolf J, et al., (2003). Bortezomib (VELCADE®, formerly PS-341) as first-line therapy in patients with multiple myeloma. Blood, 102:452a, Abstract 1650.Google Scholar
- O’Connor O, Wright J, Moskowitz CH, et al., (2003). Promising activity of the proteasome inhibitor bortezomib (VELCADE®) in the treatment of indolent non-Hodgkins lymphoma and mantle cell lymphoma. Blood, 102:636a, Abstract 2346.Google Scholar
- Orlowski RZ, Voorhees PM, Garcia RA, et al., (2003). Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Blood, 102:449a, Abstract 1639.Google Scholar
- Zangari M, Barlogie B, Jacobson J, et al., (2003). VTD regimen comprising VELCADE® (V) + thalidomide (T) and added dex (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma relapsing after autologous transplant. Blood, 102:236a, Abstract 830.Google Scholar
© Springer 2005